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1. Introduction 
Huntington’s Disease (HD) is an autosomal dominant neurodegenerative disorder clinically 
characterized by psychiatric disturbances, progressive cognitive impairment and choreiform 
movements. These symptoms are associated with the selective atrophy and neuronal loss in 
the striatum, cortex and hypothalamus. The disease is caused by a mutation at the  
5’ terminal of the huntingtin (HTT) gene involving the expansion of CAG triplet, which 
encodes for glutamine. Mutant huntingtin (mHtt) may be cleaved by proteases originating 
neurotoxic fragments, and also undergoes conformational changes that lead to the formation 
of protein aggregates (Gil and Rego 2008, for review). Among several mechanisms of 
neurodegeneration, mHtt is related to mitochondrial dysfunction and relevant changes in 
energy metabolism in both central and peripheral cells, which may underlie cell death (Gil 
and Rego 2008, for review). 
In this review chapter we emphasize the role of mitochondrial dysfunction in 
neurodegeneration in HD, particularly centering on loss of mitochondrial activity and the 
regulation of intrinsic apoptosis in central and peripheral HD human tissue or cells, and in 
animal models of HD. We focus on the changes in energy metabolism, oxidative stress, the 
link to transcriptional dysfunction and the regulation of intrinsic apoptosis. We further 
explore the therapeutic role of promoting phosphorylation pathways through selective 
inhibition of phosphatases (e.g. with FK506) and/or activation of kinase signaling cascades 
mediated by neurotrophins, namely brain-derived neurotrophic factor (BDNF) and nerve 
growth factor (NGF). 
2. Mitochondrial dysfunction and apoptosis in HD 
2.1 Mitochondrial dysfunction 
The mechanisms by which neurons die in HD are uncertain, however, mitochondrial 
dysfunction and apoptosis have been implicated. Mitochondria are important organelles 
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that regulate the life and death of cells and neurons are particularly dependent on these 
organelles due to their high energy requirements.  
Mitochondrial dysfunction is considered a common feature in the pathogenesis of 
neurodegenerative disorders like HD (Kim et al. 2010;Oliveira 2010;Parker, Jr. et al. 1990), 
and constitutes a cellular hallmark for neurodegeneration, occurring as a consequence of 
defective mitochondrial composition, trafficking to synapses, calcium handling, ATP 
production, transcription abnormalities and/or electron transport chain (ETC) impairment 
(Rosenstock et al. 2010, for review). Moreover, cell and animal models of HD exhibit 
mitochondrial impairment and metabolic deficits similar to those found in HD patients 
(reviewed in Damiano et al. 2010;Quintanilla and Johnson 2009). mHtt may cause 
mitochondrial dysfunction by directly interacting with the organelle (Panov et al. 2002) by 
evoking defects in mitochondrial dynamics, organelle trafficking and fission and fusion, 
which, in turn, may result in bioenergetic failure, or indirectly by perturbing transcription of 
nuclear-encoded mitochondrial proteins (Bossy-Wetzel et al. 2008, for review).  
The hypothesis that mitochondrial dysfunction contributes to the pathogenesis of HD was 
first tested pharmacologically by using 3-nitropropionic acid (3-NP) and malonate, 
irreversible and reversible inhibitors of succinate dehydrogenase (a component of both the 
tricarboxylic acid cycle and the complex II of the ETC), respectively. Administration of these 
inhibitors to animals results in pathological characteristics of HD, such as marked increases 
in striatal lactate concentration, striatal lesions and motor disturbances (Beal et al. 
1993;Brouillet et al. 1993;Frim et al. 1993), involving an immediate ATP drop and secondary 
increase in reactive oxygen species (ROS), which is correlated with profound mitochondrial 
fragmentation (Brouillet et al. 1999). Selective striatal neurodegeneration induced by 3-NP 
appears to be related to the early expression and activation of matrix metalloproteinase-9 by 
ROS which can digest the endothelial basal lamina, leading to the disruption of the blood–
brain barrier and to progressive striatal damage (Kim et al. 2003). Concordant with 3-NP 
mimicking the disease, in 1974 a defect in succinate dehydrogenase was reported in the 
caudate and, to a lesser extent, in the cortex of postmortem HD brains (Stahl and Swanson 
1974). Moreover, yeast expressing mHtt showed a significant reduction in oxidative 
phosphorylation due to a decrease in complexes II and III activities (Solans et al. 2006).  
Furthermore, early studies of cortical biopsies obtained from patients with either juvenile or 
adult onset HD showed abnormal mitochondria morphology and function (Goebel et al. 
1978;Tellez-Nagel et al. 1974). Functional changes in mitochondrial ETC were also observed 
in HD, namely decreased mitochondrial complexes II/III activity and succinate oxidation in 
striatal tissue from HD patients (Stahl and Swanson 1974;Gu et al. 1996;Browne et al. 
1997;Benchoua et al. 2006). Moreover, a decrease in complex IV activity was found in HD 
striatum (Browne et al. 1997;Gu et al. 1996). 
In skeletal muscle, mHtt was reported to affect the activity of mitochondrial complex I 
(Arenas et al. 1998) and also complexes II/III (Ciammola et al. 2006;Turner et al. 2007), along 
with mitochondrial depolarization, cytochrome c release and caspases activation (Ciammola 
et al. 2006;Turner et al. 2007). In platelets from HD patients, some authors also found a 
decrease in complex I activity (Parker, Jr. et al. 1990), whereas others reported no changes in 
the activity of mitochondrial complexes (Gu et al. 1996;Powers et al. 2007a). A decrease in 
mitochondrial complex II/III activity was also found in lymphoblasts of HD patients (Sawa 
et al. 1999). No significant differences were observed in complexes I and IV but a correlation 
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was found between complex II/III activity and disease duration and progress and inclusion 
formation in muscle (Turner et al. 2007).  
Cybrids, an ex-vivo human peripheral cell model in which the contribution of mitochondrial 
defects from patients may be isolated, are an interesting approach to study mitochondrial 
dysfunction (King and Attardi 1989). Results from our laboratory showed that HD cybrids, 
prepared from the fusion of HD human platelets with NT2 rho0 cells, depleted of 
mitochondrial DNA, did not exhibit significant modifications in the activity of ETC 
complexes I–IV or specific mitochondrial DNA (mtDNA) sequence variations, suggestive of 
a primary role in mitochondrial susceptibility in the subpopulation of HD carriers studied 
(Ferreira et al. 2010). In accordance, Swerdlow and collaborators (1999) showed that HD 
cybrids did not present changes in ETC activity, oxidative stress or calcium homeostasis. 
Despite unchanged activity of mitochondrial complexes, this cell model presented evidences 
of mitochondrial dysfunction based on significant changes on mitochondrial membrane 
potential and increased ROS generation (Ferreira et al. 2010). The presence of mtDNA 
variations, including an 8656A N G variant in one patient, was previously shown in a 
screening study for mutations in the tRNA(leu/lys) and MTATP6 genes of 20 patients with 
HD (Kasraie et al. 2008). However, the nucleotides 8915-9207 of the same gene did not 
present any sequence variation in our HD cybrids (Ferreira et al. 2010). One of our HD 
cybrid lines carried the 3394T N C mutation with status “unclear” (Ferreira et al. 2010), 
previously described in cases suffering from Leber Hereditary Optic Neuropathy (LHON), 
which was shown to be related with HD features (Morimoto et al. 2004). In addition, a 
decrease in mitochondrial DNA content was found in cerebral cortex of HD patients 
(Horton et al. 1995). 
It is accepted that mHtt not only impairs mitochondrial function, but also compromises 
cytosolic and mitochondrial calcium homeostasis, which contributes to neuronal 
dysfunction and death in HD (Damiano et al. 2010;Quintanilla and Johnson 2009, for 
review). Multiple changes in mitochondrial calcium handling (Panov et al. 2002;Oliveira et al. 
2007), metabolism (Damiano et al. 2010), and susceptibility to apoptosis (Sawa et al. 1999) 
were suggested to be related with mitochondrial localization of mHtt (Orr et al. 2008). 
Indeed, mHtt interaction with neuronal mitochondria of YAC72 transgenic mice (Panov et 
al. 2002) was directly linked to mitochondrial calcium abnormalities (Choo et al. 2004;Panov 
et al. 2002). In this respect our group has also demonstrated changes in calcium handling 
linked to mitochondrial dysfunction in striatal neurons from YAC128 HD mice and cells 
derived from knock-in mice (Oliveira et al. 2006). Interestingly, increased vulnerability of 
striatal mitochondria to calcium loads was found to be present in both intact neurons and 
astrocytes, when compared with their cortical counterparts. Moreover, a lower 
mitochondrial calcium buffering capacity in intact striatal versus cortical astrocytes, 
associated with increased cyclosporin A-dependent permeability transition, suggested that 
the striatum is at higher risk for disturbed interactions between neurons and astrocytes 
(Oliveira and Goncalves 2009). 
Various mitochondrial abnormalities observed in human patient samples, postmortem HD 
brains, cellular, invertebrate and vertebrate models of the disease, cooperate with 
mitochondrial ETC dysfunction in the genesis of HD (Pandey et al. 2010, for review). These 
include imbalance of calcium buffering capacity and oxidative stress, impaired axonal 
transport and abnormal fission and fusion of mitochondria, which are further described in 
this Chapter. 
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2.2 Altered mitochondrial trafficking and dynamics 
Mitochondrial shape and structure are maintained by mitochondrial fission and fusion and 
disruption of mitochondrial dynamics was shown to be involved in HD (Chen and Chan 2009, 
for review). Fission is controlled by dynamin-related protein 1 (Drp1), mostly localized in the 
cytoplasm and in the mitochondrial outer membrane (MOM), and fission 1 (Fis1), localized to 
the MOM. On the other hand, mitochondrial fusion is ruled by mitofusin 1 (Mfn1) and 
mitofusin 2 (Mfn2), localized in the MOM, and optic atrophy-1 (Opa1), localized in the 
mitochondrial inner membrane (MIM) (Chen and Chan 2009, for review). In a healthy neuron, 
fission and fusion mechanisms balance equally and mitochondria alter their shape and size to 
move from cell body to the axons, dendrites, and synapses, and back to the cell body through 
mitochondrial trafficking. Recently, a role for abnormal mitochondrial networking in HD 
pathogenesis was described, involving mitochondrial fragmentation and cristae alterations, in 
different cellular models of HD (lymphoblasts from HD patients, striatal progenitor cell lines 
isolated from knock-in HdhQ111 mouse embryos and in YAC128 primary striatal neurons), 
explaining their increased susceptibility to apoptosis (Costa et al. 2010). Thus, increased 
cytotoxicity induced by overexpression of Htt proteins containing expanded polyglutamine 
(polyQ) tracts is likely mediated, at least in part, by an alteration in normal mitochondrial 
dynamics, which results in increased mitochondrial fragmentation (Wang et al. 2009). In 
striatal neurons from moderate-to-severe grade HD patients, both mitochondrial loss and 
altered mitochondrial morphogenesis have been described, with increased mitochondrial 
fission and reduced fusion (Kim et al. 2010). Indeed, mHtt was recently shown to bind the 
mitochondrial fission Drp-1 and increase its enzymatic activity (Song et al. 2011). Furthermore, 
overexpression of proteins that stimulate mitochondrial fusion attenuates the toxicity of Htt 
proteins containing expanded polyQ tracts in both HeLa cells and C. elegans (Wang et al. 2009).  
Efficient mitochondrial trafficking is especially important in neurons with long axons and 
dendrites, to ensure high metabolic energy requirements for neuronal signaling, plasticity 
and neurotransmitter release. mHtt impairs axonal transport of mitochondria, decreases 
mitochondrial function and damages neurons in affected regions of HD patients’ brains 
(Shirendeb et al. 2011). In particular, specific N-terminal fragments of mHtt (produced 
before aggregate formation) were shown to preferentially associate with mitochondria in 
vivo, in an age-dependent way, directly affecting the mitochondrial traffic in an HD-knock-
in mouse model (Orr et al. 2008). In rat cortical neurons expressing full-length mHtt, an early 
event in HD pathophysiology is the aberrant mobility and trafficking of mitochondria 
caused by cytosolic Htt aggregates (Chang et al. 2006). Sequestration of mitochondrial 
proteins along with defective trafficking might lead to failure of ATP synthesis, energy 
depletion, and ultimately cell death in striatal neurons isolated from transgenic mice 
expressing mHtt with 72 glutamines (Trushina et al. 2004). Thus, disruption of 
mitochondrial trafficking in neurodegenerative diseases and abnormal mitochondrial 
dynamics, due to the perturbation of balance between fission and fusion, may mediate and 
amplify mitochondrial dysfunction in HD, compromising the supply of energy for normal 
neuronal function (Bossy-Wetzel et al. 2008, for review).  
2.3 Changes in energy metabolism 
Neurons are largely dependent on ATP to perform their functions and, thus, a decrease in 
mitochondrial energy metabolism may highly contribute to neurodegeneration. Moreover, 
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mitochondria in striatal neurons, especially in the GABAergic medium-sized spiny neurons 
(MSNs), seem to be selectively vulnerable to metabolic stress, which may contribute to the 
selective loss of these neurons in HD (Jin and Johnson 2010, for review). Evidences of altered 
energy metabolism in HD include a decrease in glucose metabolism, observed in the 
caudate, putamen and cortex of symptomatic and pre-symptomatic HD patients (Kuhl et al. 
1982;Kuwert et al. 1990). Modified glycolytic energy metabolism, in particular, has been 
described in HD patients, both in central and in peripheral tissues. This includes elevated 
levels of lactate in the striatum (Jenkins et al. 1993) and in the cortex (Jenkins et al. 
1993;Koroshetz et al. 1997), and increased lactate/pyruvate ratio in the CSF (Koroshetz et al. 
1997). However, decreased astrocytic glucose metabolism, with preserved oxygen 
metabolism, was described in the striatum of early symptomatic HD patients (Powers et al. 
2007b). A significant decrease in phosphocreatine/inorganic phosphate ratio was found in 
resting muscle (Koroshetz et al. 1997) of HD patients, evidencing bioenergetic changes in HD 
peripheral tissues. Previous studies showed low levels of phosphocreatine/inorganic 
phosphate ratio in muscle of HD patients, compared to control subjects (Lodi et al. 2000), 
and a delayed recovery of phosphocreatine levels in HD patients in response to exercise 
(Saft et al. 2005). Moreover, reduced ATP production was observed in muscle of both 
presymptomatic and symptomatic HD patients (Lodi et al. 2000). In fact, the onset of energy-
related manifestations at the presymptomatic stages of the disease, such as alterations in 
brain and muscle metabolism and weight loss, suggest that the energy deficit is likely to be 
an early phenomenon in the cascade of events leading to HD pathogenesis (Mochel and 
Haller 2011). Conversely, in HD N171-82Q mice model, increased glucose metabolism and 
ATP levels were found in brain tissue, suggesting that the neuronal damage in HD tissue 
may be associated with increased energy metabolism at the tissue level, leading to modified 
levels of various intermediary metabolites (Olah et al. 2008). Interestingly, we observed that 
HD cybrid lines exhibited increased glycolytic ATP levels compared to control cybrids, 
which were correlated with increased lactate/pyruvate levels (Ferreira et al. 2011). In these 
cybrids, the activity of G6PD, a key enzyme of the pentose phosphate pathway, was 
decreased (Ferreira et al. 2011), suggesting that glucose metabolization occurs primarily 
through the glycolytic pathway. Furthermore, mitochondrial NADH/NADt ratio was 
decreased (Ferreira et al. 2011), which was further correlated with a large decrease in the 
activity and protein levels of pyruvate dehydrogenase (PDH) (Ferreira et al. 2011). 
Nevertheless, the activity of alpha-ketoglutarate dehydrogenase (KGDH), another NADH 
producer in the tricarboxylic acid cycle, was increased, suggesting a compensatory 
mechanism to counterbalance the decrease in NADH production through the PDH. 
Decreased PDH activity was also previously observed in the caudate and putamen of HD 
patients (Sorbi et al. 1983), which was correlated with increasing duration of the illness 
(Butterworth et al. 1985). Moreover, PDH expression was shown to decrease with age in the 
striatum of R6/2 transgenic mice (Perluigi et al. 2005). A decrease in mitochondrial alanine 
and an increase in mitochondrial glutamate levels observed in these cybrids may be 
interpreted as an attempt to recover ketoglutarate levels and thus mitochondrial NADH 
(Ferreira et al. 2011). Alanine levels were also found to be decreased in the CSF of HD 
patients, along with decreased pyruvate levels and increased lactate/pyruvate ratio 
(Koroshetz et al. 1997). Our results demonstrated that HD cybrid lines possess inherent 
bioenergetically dysfunctional mitochondria derived from HD patients’ platelets in the 
presence of a functional nuclear background (Ferreira et al. 2011). Mitochondrial 
www.intechopen.com
 
Huntington’s Disease — Core Concepts and Current Advances 
 
366 
dysfunction at the level of PDH, upstream the oxidative phosphorylation, affected amino 
acid metabolic fluxes and the cellular bioenergetics through glycolysis stimulation, which 
assumed a greater importance in promoting ATP production (Ferreira et al. 2011). 
2.4 Oxidative stress  
Oxidative phosphorylation at the level of mitochondrial ETC is a major source of ROS, such 
as superoxide anion (the radical formed from the direct reduction of oxygen due to electron 
leakage at the ETC), hydrogen peroxide and hydroxyl radical (the most reactive and 
unstable radical). In the absence of effective antioxidants, ROS generated by dysfunctional 
mitochondria may attack mitochondrial components, promoting intracellular oxidative 
stress and leading to protein, lipid and DNA oxidation, further contributing to 
mitochondrial dysfunction. 
Oxidative damage was shown to play an important role in the pathogenesis and progression 
of HD in the R6/2 transgenic mouse model (Perluigi et al. 2005) and also in post-mortem 
samples obtained from the striatum and cortex of human HD brain (Sorolla et al. 2010). An 
increase in DCF fluorescence, indicative of an increase in hydroperoxide levels, was also 
described in the striatum of R6/1 mice 11-35 weeks (Perez-Severiano et al. 2004). In 
accordance, we demonstrated that, under basal conditions, HD cybrids were endowed with 
a significant higher production of hydroperoxides when compared to control cybrids 
(Ferreira et al., 2010). These data differ from a previous study showing no evidence of ROS 
generation in untreated HD cybrids (Swerdlow et al. 1999); however, these authors did not 
exclude a subtle mitochondrial pathology in these cells. In agreement, we showed that HD 
cybrids are more vulnerable than control cybrids to produce superoxide upon exposure to 3-
NP or staurosporine (STS), whereas increased hydroperoxide production was mainly 
evoked by STS, suggesting that the presence of higher amounts of hydroperoxides in 
untreated HD cybrids masks the effect caused by 3-NP-induced mitochondrial inhibition 
(Ferreira et al. 2010).  
Several biomarkers of oxidative stress, such as oxidized macromolecules, were found in HD 
patients and in HD models. Oxidized DNA was found in the caudate of HD patients 
(Browne et al. 1997), whereas oxidized mtDNA was reported in the parietal cortex of late 
stage (grade 3-4) HD patients (Polidori et al. 1999). 8-Hydroxy-deoxyguanosine was also 
found in peripheral blood of HD patients (Chen et al. 2007;Hersch et al. 2006). Moreover, 
oxidized DNA markers were also found in forebrain, striatum (Tabrizi et al. 2000;Bogdanov 
et al. 2001), urine, plasma and striatal dialysates of R6/2 mice at 12 and 14 weeks of age 
(Bogdanov et al. 2001). An increase in lipid peroxidation markers was also found in HD 
human blood (Chen et al. 2007;Stoy et al. 2005) or brain (Browne et al. 1999) and in R6/2 
mouse brain (Tabrizi et al. 2000;Perez-Severiano et al. 2000). Protein oxidation markers, such 
as carbonyl levels, were also found to be increased in mitochondrial enzymes, resulting in 
decreased mitochondrial activity in the striatum of Tet/HD94 conditional HD mice (Sorolla 
et al. 2010).  
Decreased activities of the antioxidant enzymes Cu–Zn-superoxide dismutase and 
glutathione peroxidase in erythrocytes (Chen et al. 2007), and decreased catalase activity 
were found in skin fibroblasts from HD patients (del Hoyo et al. 2006). A decrease in the 
antioxidant enzyme Cu/Zn-superoxide dismutase was also observed in R6/1 mice at 35 
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weeks (Santamaria et al. 2001). Moreover, the antioxidant agents lipoic acid and BN-82451 
are neuroprotective in HD mice (R6/2 and N171–82Q lines), increasing survival and 
delaying striatal atrophy in these genetic models of HD (Andreassen et al. 2001;Klivenyi et 
al. 2003), further evidencing participation of oxidative damage in the process of 
neurodegeneration in HD. However, 3-NP in vivo exposure induced antioxidant response 
element (ARE)-dependent gene expression in cultured astrocytes through the transcription 
factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2), leading to gene expression of 
antioxidant and detoxification genes (Shih et al. 2005). 
2.5 Transcriptional deregulation 
Nuclear localization of mHtt was shown to play a role in toxicity (Saudou et al. 1998), 
possibly due to interference of the mutant protein with nuclear transcription factors and co-
factors (Benn et al. 2008;Zhai et al. 2005). Moreover, mitochondrial dysfunction in HD has 
been related to transcriptional deregulation.  
Mitochondrial gene expression is regulated in the nucleus by the transcriptional co-activator 
peroxisome proliferative activated receptor gamma coactivator 1 alpha (PGC-1alpha) (Lin et 
al. 2004;Lin et al. 2005), and in the mitochondria, by the nuclear-encoded mitochondrial 
transcription factor A (Tfam) (Kaufman et al. 2007), which also regulate mitochondrial 
function and biogenesis.  
Abnormal PGC-1alpha function was shown to result in significant mitochondrial 
impairment (Kim et al. 2010). The levels of PGC-1alpha and Tfam were found to be reduced 
in HD (Cui et al. 2006;Chaturvedi et al. 2009). Moreover, both proteins have been reported to 
be significantly reduced in brain lysates from HD patients, which was correlated with HD 
progression (Kim et al. 2010). A significant decrease in PGC-1alpha mRNA was found in the 
caudate nucleus in asymptomatic HD patients, accompanied by reduced expression of genes 
involved in energy metabolism (Cui et al. 2006). Interestingly, decreased expression of PGC-
1alpha was observed in MSNs (largely affected in HD), whereas striatal interneurons 
showed increased mRNA levels for PGC-1alpha (Cui et al. 2006) which could, at least 
partially, explain the different vulnerability of these striatal neuronal populations.  
PGC-1alpha and Tfam were also reduced in muscle biopsies and myoblast cultures from 
HD subjects (Chaturvedi et al. 2009). Transcriptional repression of PGC-1alpha by mHtt 
leads not only to mitochondrial dysfunction, but also to neurodegeneration, suggesting a 
key role for PGC-1alpha in the control of energy metabolism in the early stages of HD 
pathogenesis (Cui et al. 2006). Thermoregulatory and metabolic defects in HD transgenic 
mice also implicate PGC-1alpha in HD neurodegeneration (Weydt et al. 2006), and 
polymorphisms at the PGC-1alpha gene modify the age at onset in HD (Weydt et al. 2009). 
In accordance, activation of PGC-1alpha/peroxisome proliferator-activated receptor gamma 
(PPARgamma) seems to protect against neurodegeneration (St-Pierre et al. 2006). 
PGC-1alpha controls many aspects of oxidative metabolism, including respiration and 
mitochondrial biogenesis by co-activating and enhancing the expression and activity of 
several transcription factors, including the nuclear respiratory factors (NRF)-1 and NRF-2 
(also known as GA-binding protein, GABP), PPARgamma and the estrogen related receptor 
alpha (ERRalpha) (Scarpulla 2002;Scarpulla 2011). It was recently shown that PGC-1alpha 
downstream transcription factors NRF-1 and Tfam are genetic modifiers of HD 
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(Taherzadeh-Fard et al. 2011). PGC-1alpha is indirectly involved in regulating the expression 
of mtDNA transcription via increased expression of Tfam, which is co-activated by NRF-1 
(Scarpulla 2002;Kelly and Scarpulla 2004). Moreover, mitochondrial-dependent generation 
of ROS in HD seems to be due, at least in part, to suppression of PGC-1alpha in the presence 
of mHtt, as this transcription coactivator is required for the induction of ROS-detoxifying 
enzymes, namely Mn-superoxide dismutase and glutathione peroxidase (St-Pierre et al. 
2006), implicating PGC-1alpha as an important protector against oxidative damage in HD. 
Importantly, activation of PPARgamma was recently shown to rescue mitochondrial 
dysfunction in HD (Chiang et al. 2011). 
An important and key event in the signaling cascade that regulates PGC-1alpha expression 
is related with mitogen- and stress-activated protein kinase 1 (MSK-1) activation (Martin et 
al. 2011). MSK1 induces neuroprotection in HD, involving chromatin remodeling at the 
PGC-1 alpha promoter (Martin et al. 2011). 
cAMP response element-binding (CREB) is a major transcription factor for PGC-1alpha (Cui 
et al. 2006). CREB is widely expressed and has a well-established role in neuronal protection 
(Lee et al. 2005). mHtt was shown to interfere with CREB transcriptional processes, through 
direct interaction with CREB-binding protein (CBP) (Steffan et al. 2000) and with TATA box-
binding protein (TBP)-associated factor TAF4/TAFII130 (Dunah et al. 2002;Shimohata et al. 
2000), leading to an increase in mHtt-induced cytotoxicity (Steffan et al. 2001). TAFII130 is a 
co-factor for CREB-dependent transcriptional activation that binds to polyQ, strongly 
suppressing CREB-mediated transcription (Shimohata et al. 2000). Reduction in cAMP levels 
in HD mice and HD patients likely contributes to the significant reduction in CREB 
activation (Gines et al. 2003). Moreover, CBP co-localizes with mHtt (Nucifora, Jr. et al. 2001), 
being found in nuclear inclusions in HD mice (Nucifora, Jr. et al. 2001;Steffan et al. 2001) and 
human brain (Nucifora, Jr. et al. 2001). In accordance, CRE-response genes such as 
corticotrophin-releasing hormone, proenkephalin, substance P were found to be reduced in 
brain tissue in HD patients (Augood et al. 1996;De Souza 1995) and R6/2 mice (Luthi-Carter 
et al. 2002).  
Our group has previously shown that dysregulation of CREB activation and histone 
acetylation occurs in 3-NP-treated cortical neurons (Almeida et al. 2010), an in vitro model of 
mitochondrial complex II inhibition in HD. The phosphorylation status of CREB is critical 
for its activity and several protein kinases, such as calcium/calmodulin-dependent kinase II 
and IV, protein kinase C, PI3K, Akt, MAPK, and Rsk2, have been reported to promote the 
activation of CREB (Yamamoto et al. 1988;Matthews et al. 1994;Du and Montminy 1998;Bito 
et al. 1996;Impey et al. 1998;Perkinton et al. 2002). Phosphorylation on Ser133 leads to CREB 
activation and promotes the transcription of a large number of genes, through interaction 
with its nuclear partner CBP (Mayr and Montminy 2001). Results from our laboratory 
showed that 3-NP treatment of cortical neurons decreased both CREB phosphorylation on 
Ser133 and CBP levels (Almeida et al. 2010), strongly suggesting reduced CREB-dependent 
gene expression/activation. The decrease in CREB phosphorylation was possibly due to the 
activation of phosphatases in response to 3-NP exposure. Several studies have shown that 
calcineurin, whose expression is regulated by 3-NP (Napolitano et al. 2004), also regulate the 
duration of CREB phosphorylation (Bito et al. 1996). However, the concentration of 3-NP 
used in our study did not significantly alter calcineurin (Almeida et al. 2004). The decrease in 
total CBP levels after 3-NP exposure could be explained by an independent mechanism, 
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related with caspase-3 (Almeida et al. 2010), but not calpain activation (Almeida et al. 2004). 
CBP has previously been reported to be specifically targeted for cleavage by caspases (and 
also by calpains) at the onset of neuronal apoptosis (Rouaux et al. 2003). A decrease in CBP 
was correlated with reduced acetylation of histones H3 and H4 and with a reduction in 
CBP/p300 HAT activity, even while total HAT activity remained unchanged (Rouaux et al. 
2003). Similarly, we showed that 3-NP did not alter total HAT activity, but significantly 
decreased overall HDAC activity, likely explaining why we did not observe a reduction in 
H3 or H4 acetylation (Almeida et al. 2010). Instead, we observed an increase in both H3 and 
H4 acetylation in cortical neurons upon exposure to 3-NP. Because 3-NP induces caspase-3 
activation (Almeida et al. 2004), we hypothesized that caspase-3 plays a role in inactivating 
HDACs. On the other hand, inhibition of HDAC may constitute a mechanism of protection 
of cells exposed to mild metabolic stress. Indeed, neuroprotection induced by HDAC 
inhibitors in HD striatal cells involves more efficient calcium handling, thus improving the 
neuronal ability to cope with excitotoxic stimuli (Oliveira et al. 2006).  
mHtt was previously reported to bind p53 and upregulate its expression and transcriptional 
activity (Bae et al. 2005). It was demonstrated that some of the alterations induced by mHtt 
in mitochondrial homeostasis and cell death were dependent on p53 (Bae et al. 2005). 
Recently, mHtt expression was correlated with an increase in phosphorylated p53 at Ser15, a 
decrease in acetylation at Lys382, altered ubiquitination pattern, and oligomerization 
activity. The lack of a proper p53-mediated signaling cascade or its alteration in the presence 
of DNA damage may contribute to the slow progression of cellular dysfunction which is a 
hallmark of HD pathology (Illuzzi et al. 2011). 
Specific protein-1 (Sp1) is another transcription factor that was found to bind mHtt, 
resulting in inhibition of Sp1-mediated transcription of genes in post-mortem brain tissue of 
pre-symptomatic and symptomatic HD patients (Dunah et al. 2002), such as NGF receptor 
(Li et al. 2002). Sp1 is a regulatory protein that binds to guanine-cytosine boxes and mediates 
transcription through its glutamine-rich activation domains which target components of the 
basal transcriptional complex, such as TAFII130 (Sugars and Rubinsztein 2003,for review). 
Furthermore, it has also been shown that, despite normal protein levels and nuclear binding 
activity, the binding of Sp1 to specific promoters of susceptible genes is significantly 
decreased in transgenic HD mouse brains, striatal HD cells and human HD brains, 
suggesting that mHtt dissociates Sp1 from target promoters, inhibiting the transcription of 
specific genes (Chen-Plotkin et al. 2006). Sequestration of Sp1 and TAFII130 into nuclear 
inclusions leads to the inhibition of Sp1-mediated transcription (Dunah et al. 2002;Li et al. 
2002). Moreover, shorter N-terminal Htt fragments, which are more prone to misfold and 
aggregate, are more competent to bind and inhibit Sp1 (Cornett et al. 2006). Interestingly, 
this effect was reversed in vitro by HSP40, a molecular chaperone that reduces mHtt 
misfolding (Cornett et al. 2006). 
mHtt may also lose the ability to bind and interact with other transcription factors regulated 
by wild-type huntingtin (Htt), as is the case of the neuron-restrictive silencer element 
(NRSE)-binding transcription factors, in which the failure of mHtt to interact with 
transcriptional factor complex repressor-element-1 transcription factor (REST)/neuron-
restrictive silencer factor (NRSF) in the cytoplasm leads to its nuclear accumulation. There, it 
binds to NRSE sequences and promotes histone deacetylation, leading to the remodeling of 
the chromatin into a closed structure, resulting in the suppression of NRSE-containing 
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genes, including the bdnf gene (Zuccato et al. 2003). In this case, the loss of the normal Htt 
function may have profound effects, leading to decreased levels of BDNF, an important 
survival factor for striatal neurons (section 2.2). Indeed, BDNF-knockout models were 
shown to largely recapitulate the expression profile of human HD (Strand et al. 2007), 
suggesting that striatal MSNs suffer similar insults in HD and BDNF-deprived 
environments.  
2.6 Regulation of mitochondrial-driven apoptosis 
Neurodegeneration in HD has been associated with increased cell death by apoptosis, 
particularly by the intrinsic pathway, highly regulated by mitochondria. Previous studies 
demonstrated the presence of caspases cleavage sites in Htt, a mechanism that may also 
contribute to apoptotic death by generating truncated toxic fragments of this protein 
(Wellington et al. 1998), although the CAG length does not seem to modulate the 
susceptibility for cleavage. mHtt is a substrate for several caspases and calpains (Kim et al. 
2001) and the polyglutamine fragments of Htt may present enhanced toxicity, promoting 
caspases activation by interfering with mitochondrial function, thus amplifying the 
generation of toxic truncated mHtt (Graham et al. 2010). Moreover, sequestration of pro-
caspases in the aggregates is thought to promote their activation, triggering an intracellular 
cascade of proteolytic events (Gil and Rego 2008, for review). Interestingly, wild-type Htt 
was found to have antiapoptotic properties against a variety of apoptotic stimuli, including 
serum withdrawal, death receptors, and proapoptotic Bcl-2 homologs (Rigamonti et al. 
2000), namely through inhibition of cytochrome c-dependent procaspase-9 processing and 
activity (Rigamonti et al. 2001). Furthermore, calpain (Gafni and Ellerby 2002), caspase-1 
(Ona et al. 1999) and caspase-8 (Sanchez et al. 1999) activities are increased in HD human 
brains, suggesting that an apoptotic mechanism is responsible for HD neuronal loss (Gil and 
Rego 2008, for review). Moreover, cultured blood cells from patients homozygous for CAG 
repeat mutations and heterozygous with high size mutations causing juvenile onset 
presented significantly increased caspases -2, -3, -6, -8 and -9 activities, decreased cell 
viability and pronounced mitochondria morphological abnormalities, compared with cells 
from HD patients carrying low mutation size and controls (Squitieri et al. 2011).  
Cell death by necrosis and apoptosis, along with energy deficiency, were previously 
described in striatal, cortical and hippocampal cells exposed to 3-NP (Behrens et al. 
1995;Pang and Geddes 1997;Almeida et al. 2004;Almeida et al. 2006;Brouillet et al. 2005), and 
both processes of cell damage have been proven to involve mitochondria (Kroemer and 
Reed 2000). Concordantly with a higher role of intrinsic apoptosis in HD, Ferrer and 
collaborators (2000) found a reduction in Fas and FasL expression levels in the caudate and 
putamen of HD patients. Mitochondria has been largely recognized to play a critical role in 
cell death by releasing apoptogenic factors, such as cytochrome c and apoptosis-inducing 
factor (AIF), from the intermembrane space into the cytoplasm.  
As described before, by directly interacting with the mitochondria (Panov et al. 2002), mHtt 
may cause mitochondrial abnormalities in HD, leading to cytochrome c release (Panov et al. 
2002), and a decrease in mitochondrial membrane potential (Sawa et al. 1999). Release of 
cytochrome c along with the activation of caspases -1, -8, and -9 have been demonstrated in 
HD (Ona et al. 1999;Sanchez et al. 1999;Kiechle et al. 2002), and increased Bcl-2 and Bax were 
also reported in HD patients’ brain, especially in the most severely affected (Vis et al. 2005). 
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Overexpression of mHtt, but not the normal protein, increases oxidative stress-induced 
mitochondrial fragmentation in HeLa cells, which correlates with increased caspase-3 
activation and cell death (Wang et al. 2009). Results from our laboratory highly suggested 
that 3-NP induces both caspase-dependent and -independent cell death (Almeida et al. 
2006). Our group also showed that exposure of HD cybrid cell lines to 3-NP or STS caused 
DNA fragmentation and moderate caspase-3 activation, evidencing an increased 
susceptibility of HD cybrids to apoptosis (Ferreira et al. 2010). In contrast, 3-NP-treated 
control cybrids died predominantly by necrosis, not involving caspase-3 activation (Ferreira 
et al. 2010), suggesting that HD mitochondria are endowed with pro-apoptotic machinery 
and thus more susceptible to this type of cell death. Moreover, preserved ATP in HD 
cybrids compared to control cybrids (Ferreira et al. 2011) may facilitate apoptotic cell death. 
Mitochondrial-dependent apoptosis in HD cybrids subjected to 3-NP was correlated with 
increased release of mitochondrial cytochrome c, AIF, Bax translocation, caspase-3 activation 
and ROS formation (Ferreira et al. 2010). Increased mitochondrial Bim and Bak levels, and a 
slight release of cytochrome c in untreated HD cybrids further explained their moderate 
susceptibility to mitochondrial-dependent apoptosis under basal conditions (Ferreira et al. 
2010). These data appear to be consistent with possible subtle effects of mHtt in the 
mitochondria of HD cybrids. 3-NP has been also shown to collapse mitochondrial 
membrane potential and to downregulate striatal Bcl-2 levels (Zhang et al. 2009b), 
promoting cytochrome c release from mitochondria, transient caspase-9 processing, 
activation of calpains and subsequent striatal apoptosis (Bizat et al. 2003;Zhang et al. 2009b). 
3-NP-induced decrement in Bcl-2 may also play a role in mitochondrial-dependent 
autophagy activation (through the release of Beclin 1 from hVps34 complex), which was also 
involved in striatal neuronal apoptosis (Zhang et al. 2009a).  
Our group has also reported that 3-NP causes mitochondrial-dependent apoptotic neuronal 
death through the release of cytochrome c and consequent activation of caspases, or the 
release of AIF in cortical neurons, depending on the concentration of 3-NP (Almeida et al. 
2004;Almeida et al. 2006;Almeida et al. 2009). Enhanced mitochondrial-dependent apoptosis 
was also observed in 3-NP-treated cortical neurons as a result of decreased Bim turnover 
(Almeida et al. 2004). mHtt fragments were previously shown to directly induce the opening 
of the mitochondrial permeability transition pore (PTP) in isolated mouse liver 
mitochondria, with the consequent release of cytochrome c (Choo et al. 2004), which evokes 
caspase cascade activation. Choo and collaborators (2004) also described that mitochondria 
from liver of knock-in mouse model of HD and from homozygous STHdhQ111 cells were 
more sensitive to calcium-induced cytochrome c release, swelling at lower calcium loads. An 
increased striatal mitochondrial susceptibility to the induction of permeability transition 
(Brustovetsky et al. 2003) may be responsible to the striatal selectivity for energy deficit 
associated with mHtt. An age- and polyQ-dependent decrease in the amount of calcium 
necessary to induce permeability transition in striatal mitochondria was observed in severe 
(R6/2 mice) and in mild (HdhQ92 knock-in mice) HD mouse models (Brustovetsky et al. 
2003). Moreover, increased mitochondrial calcium loading capacity, previously shown in 
isolated mitochondria from 12-13 week-old R6/2 and 12 month-old YAC mice brain 
(Oliveira et al. 2007) could constitute a compensatory mechanism, to extend neuronal 
function and survival or, alternatively, it could simply reflect an artifact resulting from 
mitochondria isolation, as it was not observed in neuronal in situ experiments following 
exposure to excitotoxic stimuli (Oliveira et al. 2007). 
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Myoblasts obtained from presymptomatic and symptomatic HD subjects also showed 
mitochondrial depolarization, cytochrome c release and increased activities of caspases -3, -8 
and -9 (Ciammola et al. 2006). In addition, peripheral blood cells, in particularly B 
lymphocytes from HD patients, may reflect changes observed in HD brain. Our group 
previously found increased Bax expression in B and T lymphocytes, and monocytes from 
HD patients, with no alterations in Bcl-2 expression levels, and decreased mitochondrial 
membrane potential in B lymphocytes (Almeida et al. 2008), further suggesting that an 
adverse effect of mHtt is not limited to neurons. Moreover, mitochondria from lymphoblasts 
of HD patients have been shown to present increased susceptibility to apoptotic stimuli due 
to an abnormal mitochondrial transmembrane potential (Sawa et al. 1999). Lymphoblasts 
derived from HD patients also showed increased stress-induced apoptotic cell death 
associated with caspase-3 activation, abnormal calcium homeostasis and mitochondrial 
dysfunction (Panov et al. 2002;Sawa et al. 1999).  
3. Protective effects involving modulation of phosphorylation pathways — 
The case of FK506 and the neurotrophins BDNF and NGF 
Even though HD has a single genetic cause, the multiplicity of pathogenic mechanisms 
involved suggests that several different targets must be taken into account in order to slow 
down HD progression. Despite important advances in elucidating the molecular pathways 
involved in HD neurodegeneration, there is currently no therapy that delays the onset of the 
disease. In this respect, stimulation of phosphorylation pathways by neurotrophins or 
calcineurin inhibitors (such as FK506) may be a promising strategy. 
3.1 FK506 — An inhibitor of calcineurin 
It is well accepted that mHtt is associated with calcium handling abnormalities (Quintanilla 
and Johnson 2009, for review). Calcineurin can be activated by abnormal calcium levels 
occurring in HD. Classically, calcineurin (or protein phosphatase 3, formerly known as 
protein phosphatase 2B) can promote apoptosis through dephosphorylation of Bad at Ser112 
and Ser136 (Wang et al. 1999), a proapoptotic member of the Bcl-2 family. Dephosphorylated 
Bad translocates from the cytosol to the mitochondria, where it inhibits antiapoptotic 
activity of Bcl-2 and Bcl-xL, ultimately leading to cell death. Calcineurin couples 
intracellular calcium to the dephosphorylation of other selected substrates, which include 
transcription factors [nuclear factor of activated T-cells (NFAT)], ion channels (inositol-1,4,5 
triphosphate receptor), proteins involved in vesicular trafficking (amphyphysin, dynamin), 
scaffold proteins (AKAP79), and phosphatase inhibitors (DARPP-32 inhibitor-1) (Aramburu 
et al. 2000).  
Calcineurin was recently shown to be involved in the dephosphorylation of Drp1, thus 
increasing Drp1 association with mitochondria and promoting fission, cristae disruption, 
cytochrome c release and apoptosis (Costa et al. 2010;Cereghetti et al. 2010). Concordantly, 
the calcineurin inhibitor PPD1 blocked Drp1 translocation to mitochondria and 
fragmentation of the organelle, delaying intrinsic apoptosis by preventing fragmentation 
and release of cytochrome c, suggesting an important function of calcineurin in 
mitochondrial fragmentation and in the amplification of cell death (Cereghetti et al. 2010).  
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FK506, also known as tacrolimus, is a selective inhibitor of calcineurin (Griffith et al. 1995) 
that has shown to exert neuroprotective effects in several cellular and animal models of HD. 
Kumar and Kumar (2009) showed that systemic treatment with FK506 significantly 
improved cognitive function in a 3-NP rodent model. In the 3-NP neuronal model, we have 
previously shown that FK506 precludes cytochrome c release, activation of caspase-3 and 
DNA fragmentation in cultured cortical neurons (Almeida et al. 2004). FK506 
neuroprotection against 3-NP-induced apoptosis was associated with the redistribution of 
Bcl-2 and Bax in the mitochondrial membrane of cortical neurons (Almeida et al. 2004). 
Moreover, FK506 significantly attenuated oxidative stress as evidenced by restoring 
glutathione levels and acetylcholinesterase activity in 3-NP treated animals (Kumar and 
Kumar 2009), highlighting the therapeutic potential of this compound. In a recent study 
from our laboratory FK506 has shown neuroprotective effects against apoptosis and necrosis 
under mild cell death stimulus, in the presence of full-length mHtt, in 3-NP-treated primary 
striatal neurons and immortalized striatal cells derived from HD knock-in mice 
(STHdhQ111/Q111 mutant cells) (Rosenstock et al. 2011). 
In the context of mHtt expression, intraperitoneal injection of calcineurin inhibitors was 
shown to accelerate the neurological phenotype in R6/2 mice (Hernandez-Espinosa and 
Morton 2006), which are resistant to excitotoxicity (Hansson et al. 1999). Interestingly, 
reduced calcineurin protein levels and activity were observed in this HD animal model 
(Xifro et al. 2009). In contrast, calcineurin is involved in cell death induced by activation of 
N-methyl-D-aspartate receptors (NMDARs) in knock-in striatal cells expressing full-length 
mHtt (Xifro et al. 2008). Moreover, FK506 and the genetic inactivation of calcineurin 
protected against mHtt toxicity through increased phosphorylation of Htt (Pardo et al. 2006) 
and further ameliorated the defect in BDNF axonal transport (Pineda et al. 2009).  
3.2 BDNF and NGF — Activators of survival pathways 
Trophic support to neurons largely influences neuronal survival and function. BDNF, a pro-
survival factor that is produced by cortical neurons, is necessary for the survival of striatal 
neurons in the brain. This is particularly relevant in HD since its transcription (Zuccato et al. 
2001) and axonal transport (Gauthier et al. 2004) are decreased by the presence of mHtt, 
affecting the survival of both striatal and cortical neurons. Members of the neurotrophin 
family, namely BDNF and NGF, have been suggested as therapeutic candidates to treat 
neurodegenerative disorders because they promote neuronal survival in different lesion 
models (Connor and Dragunow 1998). Indeed, implantation of NGF-secreting fibroblasts 
was found to reduce the size of adjacent striatal 3-NP lesions (Frim et al. 1993).  
Wild-type Htt was demonstrated to promote the expression of BDNF by interacting with the 
REST/NRSF in the cytoplasm, preventing this complex from translocating into the nucleus 
and binding to NRSE present in the promoter of the bdnf gene (Zuccato et al. 2003). Wild-
type Htt also promoted the vesicular transport of BDNF along the microtubules through a 
mechanism involving Htt -associated protein 1 (HAP1) and the p150 subunit of dynactin 
(Gauthier et al. 2004). Thus, wild-type Htt controls neurotrophic support and survival of 
striatal neurons by promoting BDNF transcription and vesicular transport along 
microtubules (Gauthier et al. 2004). 
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In contrast, mHtt decreases transcription of BDNF, which results in decreased production of 
cortical BDNF in HD (Zuccato et al. 2001), leading to insufficient neurotrophic support for 
striatal neurons, which then die. Accordingly, a reduction in cortical BDNF mRNA levels 
was shown to correlate with the progression of the disease in a mouse model of HD 
(Zuccato et al. 2005). In addition, BDNF-knockout models were shown to largely recapitulate 
the expression profiling of human HD (Strand et al. 2007), suggesting that striatal MSNs 
suffer similar insults in HD and BDNF-deprived environments. Moreover, mHtt appears to 
be responsible for altering the wild-type Htt ⁄HAP1⁄p150 complex, causing an impaired 
association between motor proteins and microtubules, and attenuating BDNF transport, 
which results in loss of neurotrophic support (Gauthier et al. 2004). Thus, restoring wild-
type Htt activity and increasing BDNF production are promising therapeutic approaches for 
treating HD (Zuccato et al. 2001).  
BDNF was previously shown to prevent the death of different populations of striatal 
projection neurons in a quinolinic acid model of HD (Perez-Navarro et al. 2000;Kells et al. 
2004) and in striatal neurons exposed to 3-NP (Ryu et al. 2004). The effects of BDNF are 
mainly mediated by TrkB receptor-induced activation of key signaling pathways, including 
phosphoinositide phospholipase C (PLC-γ), rat sarcoma GTPase (Ras)/MEK/ Ras–mitogen-
activated protein kinase (MAPK) and PI3K/Akt pathways (Huang and Reichardt 2003), 
which have been shown to regulate apoptotic cell death by increasing the transcription of 
neuroprotective proteins such as Bcl-2 (Pugazhenthi et al. 2000) and/or by posttranslational 
modifications of proteins such as Bad and Bim (Scheid et al. 1999;Luciano et al. 2003). Bim 
phosphorylation by MAPK promotes its subsequent ubiquitination and degradation (Ley et 
al. 2003), whereas serine phosphorylation of Bad is associated with protein 14-3-3 binding 
and inhibition of Bad-induced cell death (Masters et al. 2001). Data from our laboratory 
support an important role for BDNF in protecting cortical neurons against apoptotic cell 
death caused by 3-NP through the activation of PI3K and MEK1/2 intracellular signaling 
pathways and the regulation of Bim turnover (Almeida et al. 2009). Moreover, signaling of 
BDNF and NGF culminates in the transcription of neuroprotective proteins through the 
activation of critical transcription factors such as CREB and nuclear factor-kB (NFkB) 
(Huang and Reichardt 2003). As described in section 1.5, when activated by 
phosphorylation, CREB binds to its co-activator CBP and the complex is competent to 
initiate gene transcription (Mayr and Montminy 2001). Similarly, phosphorylation of IkB 
releases the p65:p50 NFkB heterodimers, which then translocate to the nucleus to initiate 
transcription. Pro-survival proteins whose expression is dependent on these transcription 
factors include proteins such as Bcl-2, Mn-superoxide dismutase and BDNF (Saha et al. 
2006). A recent study from our laboratory also suggested that BDNF and NGF induce 
positive changes in the levels and activities of CREB and NFkB, and both neurotrophins 
counteracted 3-NP-induced chromatin-bound histone acetylation modifications. The latter 
finding was correlated with BDNF-induced hyperphosphorylation of HDAC2, explaining 
the neuroprotective role of this neurotrophin in the context of mitochondrial dysfunction 
(Almeida et al. 2010).  
4. Conclusions 
In summary, biochemical studies support the view that mitochondrial dysfunction, 
including impaired oxidative phosphorylation, tricarboxylic acid cycle dysfunction, and 
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oxidative stress are important determinants of altered energy metabolism in HD. 
Bioenergetic changes in HD may be related with impaired intracellular transport and 
transcriptional deregulation in the disease (Mochel and Haller 2011). Impaired bioenergetics 
in HD likely represents downstream effects of both a mHtt toxic gain-of-function and a loss-
of-function of the wild-type protein. Thus, therapeutic strategies designed to improve 
energy metabolism and survival pathways dependent on kinase signaling in the HD brain 
will possibly impact the course of the disease, delaying its onset and the rate of progression. 
BDNF support (which can be rescued by wild-type Htt) and FK506 may have important 
therapeutic effects as enhancers of phosphorylation pathways, preventing mitochondrial 
dysfunction caused by mHtt and mitochondrial-dependent apoptosis. 
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which collectively provide comprehensive description of the key issues in the area.
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